Sven Francque

Dec 9, 2024 | nature.com | Violeta Raverdy |Federica Tavaglione |Sami Qadri |Jimmy Vandel |Lisa Olsson |Joel Haas | +4 more

AbstractMetabolic dysfunction-associated steatotic liver disease (MASLD) exhibits considerable variability in clinical outcomes. Identifying specific phenotypic profiles within MASLD is essential for developing targeted therapeutic strategies. Here we investigated the heterogeneity of MASLD using partitioning around medoids clustering based on six simple clinical variables in a cohort of 1,389 individuals living with obesity.

Jul 5, 2024 | radcliffecardiology.com | Pam R Taub |Nikolaus Marx |Michel Komajda |Sven Francque

RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes.

May 30, 2024 | radcliffecardiology.com | Harriette Van Spall |Harold Bays |Sven Francque |Barbara McGowan

ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk). In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to placebo. Weight loss was sustained over 4 years.

May 29, 2024 | radcliffecardiology.com | Harold Bays |Sven Francque |Donna Ryan |Naveed Sattar

Video Published: Views: 34 Likes: 0 Average (ratings) ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk). This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes.

May 29, 2024 | radcliffecardiology.com | Harold Bays |Sven Francque |Barbara McGowan |Donna Ryan

Video Published: Views: 31 Likes: 0 Average (ratings) ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA. Questions1. What is the background of this combinatory approach? 2. What data did you present at ERA 24? 3. What are the challenges and opportunities in approaching combinatory treatment? 4.